338 related articles for article (PubMed ID: 34371382)
1. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
[TBL] [Abstract][Full Text] [Related]
2. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
[TBL] [Abstract][Full Text] [Related]
3. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
4. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
[TBL] [Abstract][Full Text] [Related]
5. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
6. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.
Varga Z; Lebeau A; Bu H; Hartmann A; Penault-Llorca F; Guerini-Rocco E; Schraml P; Symmans F; Stoehr R; Teng X; Turzynski A; von Wasielewski R; Gürtler C; Laible M; Schlombs K; Joensuu H; Keller T; Sinn P; Sahin U; Bartlett J; Viale G
Breast Cancer Res; 2017 May; 19(1):55. PubMed ID: 28490348
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Xpert Breast Cancer STRAT 4 Assay on the GeneXpert instrument to Assess Hormone Receptor, Ki67, and HER2 Gene Expression Status in Breast Cancer Tissue Samples.
Sewanywa L; Hale M; Michelow P; Mayne E; Wiggill T
Appl Immunohistochem Mol Morphol; 2023 Oct; 31(9):613-620. PubMed ID: 37800656
[TBL] [Abstract][Full Text] [Related]
8. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
Wirtz RM; Sihto H; Isola J; Heikkilä P; Kellokumpu-Lehtinen PL; Auvinen P; Turpeenniemi-Hujanen T; Jyrkkiö S; Lakis S; Schlombs K; Laible M; Weber S; Eidt S; Sahin U; Joensuu H
Breast Cancer Res Treat; 2016 Jun; 157(3):437-46. PubMed ID: 27220750
[TBL] [Abstract][Full Text] [Related]
9. Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.
Janeva S; Parris TZ; Nasic S; De Lara S; Larsson K; Audisio RA; Olofsson Bagge R; Kovács A
BMC Cancer; 2021 Apr; 21(1):439. PubMed ID: 33879115
[TBL] [Abstract][Full Text] [Related]
10. Use of the Xpert Breast Cancer STRAT4 for Biomarker Evaluation in Tissue Processed in a Developing Country.
Mugabe M; Ho KE; Ruhangaza D; Milner D; Rugwizangoga B; Chu VC; Wu NC; Rizo A; Weidler JM; Wong W; Bates M; Brock JE
Am J Clin Pathol; 2021 Oct; 156(5):766-776. PubMed ID: 34050358
[TBL] [Abstract][Full Text] [Related]
11. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.
Gupta S; Mani NR; Carvajal-Hausdorf DE; Bossuyt V; Ho K; Weidler J; Wong W; Rhees B; Bates M; Rimm DL
Lab Invest; 2018 Aug; 98(8):1076-1083. PubMed ID: 29858579
[TBL] [Abstract][Full Text] [Related]
12. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility of mRNA-Based Testing of
Erber R; Hartmann A; Fasching PA; Ruebner M; Stöhr R; Beckmann MW; Zentgraf M; Popp V; Weidler J; Simon I; Becker S; Huebner H; Fischer J; Guerini Rocco E; Viale G; Cayre A; Penault-Llorca F; Caniego Casas T; Pérez-Miés B; Palacios J; Jank P; Denkert C; Khoury L; Mairinger T; Ferrazzi F
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572945
[TBL] [Abstract][Full Text] [Related]
14. Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
Badr NM; Zaakouk M; Zhang Q; Kearns D; Kong A; Shaaban AM
Histopathology; 2024 Apr; ():. PubMed ID: 38651302
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of
Carretero-Barrio I; Caniego-Casas T; Rosas M; Sánchez MC; Martínez-Jáñez N; Chiva M; Sarrió D; Moreno-Bueno G; Palacios J; Pérez-Mies B
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980575
[TBL] [Abstract][Full Text] [Related]
16. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.
Du X; Li XQ; Li L; Xu YY; Feng YM
Breast Cancer Res Treat; 2013 Feb; 138(1):59-67. PubMed ID: 23397283
[TBL] [Abstract][Full Text] [Related]
17. ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).
Breyer J; Wirtz RM; Laible M; Schlombs K; Erben P; Kriegmair MC; Stoehr R; Eidt S; Denzinger S; Burger M; Hartmann A; Otto W
Virchows Arch; 2016 Nov; 469(5):547-552. PubMed ID: 27514658
[TBL] [Abstract][Full Text] [Related]
18. XPERT
Borges PCC; Spencer HB; Barbosa C; Costa V; Furtado A; Leal MC; Lopes C; Ferreira D; Carvalho AL; Dos-Santos-Silva I; Santos LL
Ecancermedicalscience; 2023; 17():1530. PubMed ID: 37138965
[TBL] [Abstract][Full Text] [Related]
19. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Subtype Classification Using 4-Plex Droplet Digital PCR.
Chen W; Zheng J; Wu C; Liu S; Chen Y; Liu X; Du J; Wang J
Clin Chem; 2019 Aug; 65(8):1051-1059. PubMed ID: 31010819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
